Search results
Results from the WOW.Com Content Network
Efbemalenograstim alfa can cause fatal splenic rupture, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, sickle cell crises in patients with sickle cell disorders, glomerulonephritis, thrombocytopenia, capillary leak syndrome, and myelodysplastic syndrome and acute myeloid leukemia in people with breast and lung cancer.
In both trials, participants were randomly assigned to either receive eflapegrastim or pegfilgrastim under the skin (subcutaneously) approximately 24 hours after anticancer treatment. [4] Participants in both groups were evaluated and compared for the duration of severe neutropenia (a condition with lower-than-normal levels of neutrophils in ...
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. [23] Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). [24] [23]
Biotech giant Amgen announced in a press release Saturday that its PAVES phase 3 trial to evaluate colorectal cancer patients taking the white blood cell-boosting drug Neulasta met its primary ...
Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause. [19] It may also be used to increase white blood cells for gathering during leukapheresis. [19] It is given either by injection into a vein or under the skin. [19] Filgrastim is a leukocyte growth factor. [18]
Pegfilgrastim (Neulasta) – PEGylated recombinant methionyl human granulocyte colony-stimulating factor for severe cancer chemotherapy-induced neutropenia (Amgen, 2002) Pegvisomant (Somavert) – PEG-human growth hormone mutein receptor antagonist for treatment of Acromegaly (Pfizer, 2002)
Matuzumab [24] mab: humanized: Epidermal growth factor receptor (EGFR) colorectal, lung and stomach cancer Mepolizumab [47] Bosatria: mab: humanized: IL-5: Y: asthma and white blood cell diseases Metelimumab [24] mab: human: TGF-β1: systemic scleroderma: Milatuzumab [13] mab: humanized: CD74: multiple myeloma and other hematological ...
The first dose should be given 6 to 24 hours after completion of chemotherapy. Dosing should be continued until platelet counts reach at least 50,000 cells. Usually, one course of Neumega encompasses 10 to 21 days. The drug should be discontinued at least 2 days before starting the next chemotherapy cycle.